NCT04123509 is a clinical trial in Gastroesophageal Varices, sponsored by Nanfang Hospital, Southern Medical University.

Who is sponsoring NCT04123509?

NCT04123509 is sponsored by Nanfang Hospital, Southern Medical University.

What condition does NCT04123509 study?

NCT04123509 studies Gastroesophageal Varices, Portal Hypertension.

Is NCT04123509 still recruiting?

NCT04123509 is currently status unknown. Last updated 11 October 2019.

Last reviewed 2019-10-11 · How we verify

NCT04123509

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Non-invasive Method for Predicting the Presence of Gastroesophageal Varices in Patients With Cirrhosis

Status unknown Last updated 11 October 2019

What this trial tests

trial in Gastroesophageal Varices in 616 participants. Status unknown.

Timeline

9 April 2019

Primary endpoint
31 December 2020

31 January 2021

Quick facts

Lead sponsor	Nanfang Hospital, Southern Medical University
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	616
Start date	9 April 2019
Primary completion	31 December 2020
Estimated completion	31 January 2021
Sites	1 location across China

Conditions studied

Gastroesophageal Varices — all drugs for Gastroesophageal Varices →
Portal Hypertension — all drugs for Portal Hypertension →

Sponsor

Nanfang Hospital, Southern Medical University

Who can join

Adults 18 to 75, any sex, with Gastroesophageal Varices or Portal Hypertension. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Gastroesophageal varices are a complication of portal hypertension in cirrhosis.Endoscopy is an unsatisfactory screening test.In this prospective clinical study,we will enroll patients with cirrhosis of various causes, all of whom undergo laboratory tests, elastography, and serum proteomic differential protein testing, including liver elastography (LSM) and spleen elastography (SSM). Baveno VI or expanded BavenoVI criteria are validated by comparing patients' LSM, SSM, serum differential protein, platelet count, and EGD data to evaluate the clinical value of SSM and differential proteins in excluding cirrhosis of cirrhosis.At the same time, based on SSM and serum differential protein, a new predictive model of variceal varices will be established to evaluate the diagnostic value of SSM and differential protein for esophagogastric varices, and a non-invasive method for reliably predicting and evaluating cirrhosis with esophageal varices will be found.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Baveno VI criteria and spleen stiffness measurement rule out high-risk varices in virally suppressed HBV-related cirrhosis.
Wang H, Wen B, Chang X, Wu Q, et al · · 2021 · cited 59× · PMID 33039403 · DOI 10.1016/j.jhep.2020.09.034
Baveno VI-SSM stratifies the risk of portal hypertension-related events in patients with HBV-related cirrhosis.
Wang H, Liang W, Zhou L, Song J, et al · · 2025 · cited 10× · PMID 39905841 · DOI 10.3350/cmh.2024.0609
Indocyanine Green Clearance Test via Pulse Dye Densitometry for Portal Hypertension Diagnosis in cACLD.
Liu M, Zhang X, Cheng X, He Q, et al · · 2025 · cited 1× · PMID 41178521 · DOI 10.1111/liv.70425

Verify or expand the search:

Other recruiting trials for Gastroesophageal Varices

Currently open trials in the same condition.

NCT04867954 — Development of 4D Flow MRI for Risk Stratification of Variceal Bleeding in Cirrhosis · recruiting
NCT04786743 — Timing of Endoscopic Intervention for Acute Variceal Hemorrhage: an RCT · NA · recruiting

Other Nanfang Hospital, Southern Medical University trials

Trials by the same sponsor.

NCT07091994 — A Trial of Edaravone Dexborneol in Acute Ischemic Stroke With Active Malignancy · Phase 4 · not yet recruiting
NCT06444022 — hAESCs Prevent Acute Graft-versus-host Disease After Hematopoietic Stem Cell Transplantation · Phase 1 · withdrawn
NCT07537777 — Benmelstobart Plus Anlotinib Combined With SBRT for Patients With Hepatocellular Carcinoma Failing First-Line Targeted T · Phase 2 · not yet recruiting
NCT07481032 — Effect of Fufang Biejiaruangan Combined With Antiviral Therapy on the Incidence of Hepatocellular Carcinoma in Patients · NA · not yet recruiting
NCT07511894 — Beta-Blockers on the Efficacy of Neoadjuvant Immunotherapy for Gastric Cancer · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04123509 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Nanfang Hospital, Southern Medical University
Last refreshed: 11 October 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04123509.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing